Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Friday, January 30, 2026 1 min read
Key Takeaway: Radiopharm Theranostics has made significant strides in its clinical programs, including the dosing of the first patient in a Phase 1/2a study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These developments highlight the company's commitment to advancing its innovative therapies.
Price reaction · baseline $4.91 (2026-01-30T19:40:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
+2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has received IND approval from the FDA.
  • The company is advancing its clinical studies with positive updates.
  • First patient has been dosed in the Phase 1/2a study of BetaBart.

Full Press Release Details

• Analyst Reports , Updates
• Video
• January 30, 2026

More Announcements & Updates

• Analyst Reports , Updates
• January 30, 2026
• Analyst Reports
• November 3, 2025
• Announcements
• February 2, 2022
• Announcements
• November 25, 2021

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the latest update from Radiopharm Theranostics?

Radiopharm Theranostics has dosed its first patient in a Phase 1/2a study of BetaBart.

What approval did Radiopharm receive from the FDA?

The company received IND approval to initiate a clinical study targeting B7H3.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic candidate being studied by Radiopharm Theranostics.

When was the first patient dosed in the clinical study?

The first patient was dosed in the Phase 1/2a clinical study recently.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA approval clinical trials
Last updated: Jan 30, 2026